The potential for NX-1207 in benign prostatic hyperplasia: an update for clinicians
Open Access
- 26 September 2011
- journal article
- research article
- Published by SAGE Publications in Therapeutic Advances in Chronic Disease
- Vol. 2 (6), 377-383
- https://doi.org/10.1177/2040622311423128
Abstract
Lower urinary tract symptoms associated with benign prostatic hyperplasia (BPH) affect many older men and can have a significant impact on health-related quality of life. BPH is a progressive condition that may lead to complications including acute urinary retention. There exists an unmet need for a safe and effective, office-based, catheter-free therapy for BPH patients. NX-1207 is a promising first-in-class drug currently in phase III trials for the treatment of BPH. This review provides an overview of the NX-1207 trial program and considers its potential application for patients with symptoms related to BPH. NX-1207 is administered as an office-based procedure by transrectal intraprostatic injection under ultrasound guidance. NX-1207 has selective pro-apoptotic properties, which induce focal cell loss in prostate tissue, leading to prostate volume reduction with both short- and long-term symptomatic improvement. In four US clinical trials to date, NX-1207 has shown evidence of symptomatic improvement substantially better than currently approved BPH medications with no significant safety issues. Larger phase III trials are ongoing to confirm further the efficacy, safety, and tolerability for this minimally invasive, anesthetic-free, clinic-based treatment for BPH.Keywords
This publication has 9 references indexed in Scilit:
- NX-1207: a novel investigational drug for the treatment of benign prostatic hyperplasiaExpert Opinion on Investigational Drugs, 2010
- Evaluating Use Patterns of and Adherence to Medications for Benign Prostatic HyperplasiaJournal of Urology, 2009
- Currently available treatment guidelines for men with lower urinary tract symptomsBJU International, 2008
- An assessment of the diagnosed prevalence of diseases in men 50 years of age or older.2006
- The natural history of benign prostatic hyperplasiaBJU International, 2006
- The American Urological Association 2003 guideline on management of benign prostatic hyperplasia: a Canadian opinion.2004
- Treatment Strategies, Patterns of Drug Use and Treatment Discontinuation in Men with LUTS Suggestive of Benign Prostatic Hyperplasia: The Triumph ProjectEuropean Urology, 2003
- The prevalence of Prostatism: A Population-Based Survey of Urinary SymptomsJournal of Urology, 1993
- The Development of Human Benign Prostatic Hyperplasia with AgeJournal of Urology, 1984